Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19019072 | 0.78 | PDE3B (0.38) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL30141680 | 0.73 | MAT2A (0.37) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL25462879 | 0.73 | ALDH1A1 (0.40) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL29985144 | 0.70 | MEN1 (0.33) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL25272619 | 0.69 | TYRO3 (0.50) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL5612934 | 0.69 | CYP1A2 (0.47) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL4573075 | 0.69 | CYP1A2 (0.47) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL6357736 | 0.68 | CXCR2 (0.42) | — | |
| SCHEMBL29985137 | 0.67 | CDK4 (0.36) | KDM4EALDH1A1LMNAGLAPMP22 | |
| SCHEMBL28647710 | 0.66 | ALDH1A1 (0.40) | KDM4EALDH1A1LMNAGLAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347756-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2021-11-11 | — | — | US | disclosed |
| US-20190192522-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN COMBINATION WITH CYCLIN-DEPENDENT KINASE INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2019-06-27 | — | — | US | disclosed |
| US-10221154-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347756-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | KDM4E 976/4885ALDH1A1 1963/4885LMNA 4186/4885 |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | KDM4E 976/4885ALDH1A1 1963/4885LMNA 4186/4885 |
| US-10221154-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | KDM4E 976/4885ALDH1A1 1963/4885LMNA 4186/4885 |
| US-20190192522-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN COMBINATION WITH CYCLIN-DEPENDENT KINASE INHIBITORS | CDK4, FGFR4, CDKL4 | KDM4E 370/4885ALDH1A1 3378/4885LMNA 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.